ライフサイエンスコーパス: disease model

1 mouse to develop a chronic long-term muscle disease model.

2 neuromuscular degeneration in a Parkinson's disease model.

3 CHFV-mediated disease in a non-human primate disease model.

4 rozygous K219T mutation on LMNA to develop a disease model.

5 o cystinotic mice provides a complex in vivo disease model.

6 al performance in 5XFAD mice, an Alzheimer's disease model.

7 of retained introns and skipped exons in our disease model.

8 discussions to construct an incidence-based disease model.

9 sing chronic lymphocytic leukemia (CLL) as a disease model.

10 d determine their concentrations in a murine disease model.

11 insulin and impaired in an insulin-resistant disease model.

12 votal role in inflammation in a mouse kidney disease model.

13 onses using a severe acute graft versus host disease model.

14 organ level, in a dysmotile gastrointestinal disease model.

15 committed to the application of the medical disease model.

16 nvestigated in a well-established alphavirus disease model.

17 rucial for the evaluation of any preclinical disease model.

18 astic gait disorders after brain injury in a disease model.

19 se findings into an anatomical-physiological disease model.

20 nts in METTL5, thereby providing a new mouse disease model.

21 of therapeutic efficacy in this large animal disease model.

22 in other inflammation- and fibrosis-related disease models.

23 models and may be applicable to other rodent disease models.

24 tter tissue fabrication, and building better disease models.

25 gnificance in normative and neuropsychiatric disease models.

26 road spectrum of viruses in multiple in vivo disease models.

27 36gamma induced responses in mouse and human disease models.

28 schemia/reperfusion (I/R) injury in multiple disease models.

29 ong-range connections and neurodevelopmental disease models.

30 developed as therapeutic agents in multiple disease models.

31 ed splicing events regulated by MBNLs in all disease models.

32 nd have been evaluated in several autoimmune disease models.

33 ded transuterine cell injection using rodent disease models.

34 has yet been developed and tested in vivo in disease models.

35 ress and elicit neurotoxicity in Parkinson's disease models.

36 t the potential of novel stem cell-based T2D disease models.

37 id lineages and examined the strain in three disease models.

38 rnosa fibrosis owing to its well-established disease models.

39 immune pathways in various neurodegenerative disease models.

40 e expression studies, functional assays, and disease models.

41 TCR-mediated NKT cell activation in various disease models.

42 n several neutrophil-associated inflammatory disease models.

43 and activators in different biochemical and disease models.

44 oxygen production in multiple cell types and disease models.

45 plits and mergers in numerous biological and disease models.

46 that was reproducible across a multitude of disease models.

47 line also restored deficiencies of Notch1 in disease models.

48 nal damage in a variety of neurodegenerative disease models.

49 ed, including pharmacological treatments and disease models.

50 is required for injury responses in diverse disease models.

51 udied both in vitro and in vivo using animal disease models.

52 protects mice from pathological bone loss in disease models.

53 ponse of mice to three distinct inflammatory disease models.

54 tress response factors protective in amyloid disease models.

55 d microglia of normal white matter in myelin disease models.

56 nctional reorganization of brain circuits in disease models.

57 ield of iPSC-based sarcomeric cardiomyopathy disease models.

58 se-associated genes with 40 as potential new disease models.

59 or to interpret neural function and validate disease models.

60 ained kidneys from various species and renal disease models.

61 egmentation performance was very high in all disease models.

62 ed as lead therapeutic constructs in several disease models.

63 nt mtDNA rNMP content has been identified in disease models.

64 ncy and are effective in several preclinical disease models.

65 thophysiology of mural cells in a variety of disease models.

66 y has shown great promises in various animal disease models.

67 interpreting urinary albumin levels in early disease models.

68 y could also be useful in other inflammatory disease models.

69 balance between these processes in relevant disease models.

70 ogy for clinical applications as well as for disease modeling.

71 ghly valuable for many applications, such as disease modeling.

72 ells has opened up new opportunities for T2D disease modeling.

73 r future use in cell replacement therapy and disease modeling.

74 for drug screening, tissue engineering, and disease modeling.

75 " represents a tool for drug development and disease modeling.

76 ish a platform to advance drug screening and disease modeling.

77 hodologies and discuss their applications in disease modeling.

78 large-scale differentiation experiments and disease modeling.

79 for drug screening, tissue engineering, and disease modeling.

80 em cell biology to regenerative medicine and disease modeling.

81 vis as a subject for biological research and disease modeling.

82 , which are important for neurodevelopmental disease modeling.

83 or pluripotent stem cell differentiation and disease modeling.

84 ls for pre-clinical toxicity testing and for disease modeling.

85 ution, genome editing and 'omics', and human disease modelling.

86 ntia, and multiple system atrophy and animal disease models; 2) provide mechanistic insights on how t

87 of TR1 cells in a murine inflammatory bowel disease model, a model that resembles the trials perform

88 In disease models, a sharp increase of proliferation and cy

89 otent stem cells (iPSC), a key cell type for disease modelling, analysing 202 iPSC lines derived from

90 eurological functions, we examined it in our disease model and found that the gut microbiota of Cln3(

91 rough bacterial infection as an inflammatory disease model and used adeno-associated virus (AAV)-medi

92 ecapitulates the pathology of a conventional disease model and/or human food allergy.

93 should facilitate hPSC-based strategies for disease modeling and cell therapy in CNS disorders.

94 erstanding underlies rapid progress in human disease modeling and cellular approaches to repair damag

95 provides a powerful platform for ENS-related disease modeling and drug discovery.

96 diomyocytes (PSC-CMs) hold great promise for disease modeling and drug discovery.

97 ise in constituting a platform for effective disease modeling and drug discovery.

98 functionality of human organs on a chip for disease modeling and drug testing, shows great potential

99 We also show its applicability for renal disease modeling and drug testing.

100 tream applications such as drug repurposing, disease modeling and gene function prediction.

101 f single nucleotide variants is required for disease modeling and gene therapy.

102 lls (hiPSCs) provide a powerful platform for disease modeling and have unlocked new possibilities for

103 and functional characterization, as well as disease modeling and in vivo validation capabilities.

104 ers unprecedented opportunities for in vitro disease modeling and personalized cell replacement thera

105 ng patient-specific differentiated cells for disease modeling and preclinical drug testing.

106 the rapid production of human astrocytes for disease modeling and regenerative medicine.

107 tine application of hPSC-derived lineages in disease modeling and regenerative medicine.

108 nes and have potential applications for both disease modeling and regenerative medicine.

109 enables the generation of new cell types for disease modeling and regenerative therapies, reprogrammi

110 ry mediators and hence may have potential in disease modeling and therapeutic development.

111 ic excision, with important implications for disease modeling and therapeutic gene editing.

112 on, demonstrating their future potential for disease modeling and therapeutic screening applications.

113 hen utilizing them in developmental studies, disease modeling and transplantation.

114 gn of differentiation protocols of hPSCs for disease modelling and cell therapy, and in high-throughp

115 egenerative medicine applications, including disease modelling and drug screening.

116 methods for small molecules, developments in disease modelling and improvements in analytical technol

117 nd offers a solution to current obstacles in disease modelling and liver tissue engineering.

118 or future studies of human skin development, disease modelling and reconstructive surgery.

119 otent stem cells into RPE cells suitable for disease modelling and therapy development.

120 ation derived from these advances to climate-disease models and addressing the pressing knowledge gap

121 strated potent protective activity in animal disease models and are thus promising candidates for the

122 tory and immunomodulatory effects in various disease models and clinical treatments.

123 Evidence comes primarily from disease models and conclusive data to support bioenerget

124 nal analysis of linked cis-elements creating disease models and correcting pathogenic mutations.

125 ic alterations in schizophrenia and relevant disease models and discuss their putative origin.

126 ney tissue from healthy mice and five murine disease models and from other species used in preclinica

127 formal semantic rules to express meaningful disease models and has expanded from a single asserted c

128 powerful tool to study gene function, create disease models and holds promise for therapeutic gene ed

129 etween neurons and glioma cells in different disease models and human tumours: functional bona fide c

130 bialis anterior muscle in wild-type mice and disease models and increased ankle dorsiflexion torque i

131 ralized to other systems through a rubric of disease models and parameters that can be derived from e

132 d in previously published studies from other disease models and patients with glomerular damage.

133 behavior provides context for understanding disease models and physiology.

134 Animal disease models and several ongoing human clinical trials

135 roach has also broader applications to other disease models and tissues.

136 ological pathways, which may help to improve disease models and treatment approaches.

137 of age specificity in leukemia could improve disease models and uncover new therapeutic approaches.

138 client proteins that are altered in vivo in disease models and whose degradation is promoted by UBQL

139 ic disorders, with direct advantages for the disease-modeling and human genetics communities.

140 as generated opportunities for heart repair, disease modeling, and drug development.

141 velopmental biology, regenerative therapies, disease modeling, and drug discovery.

142 tic biomedical research, drug discovery, and disease modeling, and engineering applications.

143 rces in order to support precision medicine, disease modeling, and mechanistic exploration.

144 hroughput/content screening, drug discovery, disease modeling, and personalized medicine.

145 orm for in vitro studies of kidney function, disease modeling, and pharmacology.

146 e editing applications in synthetic biology, disease modeling, and regenerative medicine.

147 , novel clinical trial designs, pre-clinical disease modeling, and understanding recovery from acute

148 ral-development investigation, drug testing, disease modelling, and examining novel cellular replacem

149 to enable faecal host DNA studies in animal disease models as well.

150 in vivo mitophagy reporter methodologies and disease models, as well as patient stratification and bi

151 advances in the research fields of genetics, disease modelling, biomarkers, and therapeutic strategie

152 tive 1 was studied in an acute in vivo mouse disease model but unfortunately showed no efficacy due t

153 This new concept of metabolic disease modeling by somatic genome editing could be appl

154 ur findings were validated in two autoimmune disease models by demonstrating that lack of DO increase

155 to represent the usage of cell line cells as disease models by inducing tumor formation in model orga

156 ic effect and showed improvements on dry eye disease models by stabilizing the tear film, scavenging

157 Disease models can be created by the use of patient-deri

158 patients' CD4(+) T cells and a novel murine disease model caused by overactive PI3K signaling.

159 g drives constitutive mTORC1 activation in a disease model caused by the loss of the lysosomal choles

160 In disease models, computational feature extraction reveale

161 ting one of the earliest defects observed in disease models, contributing to denervation and motoneur

162 The combination of hiPSC-based disease modeling, CRISPR technology, and high-throughput

163 Here, drawing from extensive human and disease model data, we highlight the latest evidence bas

164 Recent applications in marine disease modeling demonstrate that physical oceanographic

165 In contrast, in a disseminated disease model designed to reflect low-burden MRD, 3 stud

166 h3tc2-/- mice represent a well characterized disease model developing early onset progressive periphe

167 Recent work has shown that mitochondrial disease models display tissue hyperoxia and that disease

168 provides powerful opportunities for in vitro disease modeling, drug discovery, and personalized stem

169 mimicry that may have broad implications for disease modeling, drug discovery, and regenerative engin

170 s has the potential to produce podocytes for disease modeling, drug screening, and cell therapies.

171 constitute a potential cell source for heart disease modeling, drug screening, and cell-based therape

172 remains a key challenge for applications in disease modeling, drug screening, and heart repair.

173 rrently a challenge for their application in disease modeling, drug screening, and regenerative medic

174 lications of bioprinted microvasculature for disease modeling, drug testing, and tissue engineering,

175 , which holds much promise as a platform for disease modelling, drug development and regenerative the

176 ntelligence and patient-derived experimental disease models during the progression from health to dis

177 hemodynamics (e.g. brain), other preclinical disease models (e.g. stroke), vascular-targeted therapeu

178 ganoids and focus on their applicability for disease modeling, evolutionary studies and neural networ

179 rome is primarily a synaptic disorder, and a disease model for both intellectual disability and autis

180 unocompetent mouse model that can serve as a disease model for multiple flaviviruses.

181 unocompetent mouse model that can serve as a disease model for multiple flaviviruses.IMPORTANCE Flavi

182 eta cells for cell replacement therapies and disease modeling for diabetes.

183 rative medicine but also in drug testing and disease modeling for osteoarthritis.

184 ructs for tissue repair and build biomimetic disease models for studying disease biology and screenin

185 o decreased median pediatric end-stage liver disease/model for end-stage liver disease at transplant

186 sms of contact behavior into a generalizable disease modeling framework.

187 IV (azide) Danio rerio vertebrate zebrafish disease models from brain death.

188 eed, an induced pluripotent stem cell (iPSC) disease model has been used to test patient-specific cel

189 This disease model has been validated because genetic modifie

190 Infectious disease modeling has played a prominent role in recent o

191 ion of cerebral microvessels in experimental disease models has been hindered by the lack of a standa

192 ol, however application to neurodegenerative disease models has been limited.

193 ng has not been fully characterized, as most disease models have been based on overexpressing mutant

194 tial and temporal heterogeneities in retinal disease models have hampered validation of this hypothes

195 Several metabolic disease models have shown that dysregulation of sarcopla

196 is an unrivalled comparator for neurological disease modeling, however canine brain morphometric dive

197 ed phenotypes in a cystic fibrosis-like lung disease model (i.e., Scnn1b-Tg-positive [Tg+]) mouse, re

198 In both disease models, IL-4Ralpha-responsive B cells displayed

199 ight that better approximates the underlying disease model in a data-adaptive manner.

200 se and representing a norovirus small animal disease model in wild-type mice.

201 lity of multiplex base editing for polygenic disease modeling in primate zygotes.

202 ynamic analysis in human study participants, disease modeling in rodents, and cell-based assays, we e

203 by manipulating SRSF6 levels in Huntington's disease models in which an expanded CAG repeat had been

204 a revised concept of an integrative unified disease model, in which lamin-mediated pathways in mecha

205 vivo demonstrates promising results in many disease models, in which autophagy upregulation is able

206 Patient-derived disease models including neural progenitor cells and cer

207 various pathologic processes in preclinical disease models, including pulmonary fibrosis, thrombosis

208 ulating evidence from both human studies and disease models indicates that intercellular transmission

209 n of patient-specific, isogenic control, and disease modeled induced pluripotent stem cell (iPSC) lin

210 t, which include improvements to mechanistic disease models, investigations into the importance of cl

211 Additionally, patient and disease modeled iPSC-CMs displayed impaired Ca(2+) handl

212 Compared with controls, both patient and disease modeled iPSC-CMs were significantly larger and d

213 ice for drug screening studies, when a valid disease model is available.

214 zation across individuals, brain regions, or disease models is challenging.

215 hat contributes to arrhythmogenesis in heart disease models, is a candidate therapeutic target in CPV

216 tective in a wide range of neurodegenerative disease models, it also inhibits axonal regeneration.

217 n a classic mouse obstructive chronic kidney disease model, largely in the interstitial FSP-1-positiv

218 s in wild-type or in other neurodegenerative disease models may have an altered impact in the HD cont

219 Temporally resolved imaging of AKI-disease model mice with KNP-1 suggests a gradual increas

220 with the ultimate goal of making future drug-disease models more versatile and realistic.

221 suggests that any repair mechanism with this disease model must trigger a secondary process.

222 e aggregated at county or coarser scales, so disease models must rely on assumptions about how indivi

223 us from healthy mice and from four different disease models (nephrotoxic serum nephritis, diabetes, d

224 unction, mutant phenotypes, orthology, human disease models, nomenclature and reagents.

225 a human induced pluripotent stem cell (iPSC) disease model of a common form of heart disease involvin

226 ny), and confocal images of an in vivo mouse disease model of aspergillus fumigatus pneumonia.

227 uman tissues to SARS-CoV-2 infection and for disease modeling of COVID-19.

228 cance of this new culture medium for chronic disease modeling of IL-13-induced airway hyper-responsiv

229 em (PS) cells into myotubes enables in vitro disease modeling of skeletal muscle diseases.

230 Using excellent disease models of infection in natural avian hosts, we s

231 lgorithm to cardiomyocytes isolated from rat disease models of myocardial infarction (MI), dilated ca

232 bition of the inflammasome rescued zebrafish disease models of neutrophilic inflammation and anemia.

233 ntral findings in different cell biology and disease models of senescence.

234 y for a fundamental rethink about the "brain disease model" of addiction that dominates research, tre

235 dings suggest that patient-specific neuronal disease modelling offers a useful platform for discoveri

236 ection as well as to establish phenotypes in disease modeling or toxicity studies.

237 challenges that are unique to human in vitro disease models, particularly interdonor and intradonor v

238 or a variety of applications such as ex vivo disease modeling, personalized drug testing or metabolic

239 From pathogenesis to disease modeling, pharmaceuticals to vaccines, immunolog

240 ively reduced levels of the cluster in three disease models: polycystic kidney disease, prostate canc

241 Historically, the structural disease model proposed mechanical defects of the lamina

242 rs a significant therapeutic benefit in this disease model, providing a proof of principle for treati

243 This is partly due to the lack of disease models recapitulating the human pathology.

244 s, and our methods are applicable to various disease models regardless whether the underlying true mo

245 e a fully faithful reproduction of the human disease, models remain essential as tools to improve our

246 Spatially explicit livestock disease models require demographic data for individual f

247 tic ablation of miR-128-1 in mouse metabolic disease models result in increased energy expenditure an

248 Analysis of the disease models revealed cell type-specific and injury ty

249 In a C. elegans Alzheimer's disease model, SKN-1A/Nrf1 slows accumulation of the amy

250 tic potential of cysteamine bitartrate in RC disease models spanning three evolutionarily distinct sp

251 The integrative disease-modelling strategy may reveal new insights into

252 ification of changes in gene expression in a disease model (stroke) and the activation of signaling p

253 l effect of RA has been reported in multiple disease models, such as glomerulosclerosis, renal fibros

254 Current disease models suggest that chytrid fungi locate and inf

255 Foundation, Global Good Fund, Institute for Disease Modeling, Swiss National Science Foundation, and

256 fibrils and are known to cause cell death in disease model systems.

257 ting CRISPR Engineering and hiPSC-Derived 2D Disease Modeling Systems, by Kristina Rehbach, Michael B

258 HD in a nonsclerodermatous multiorgan system disease model that includes bronchiolitis obliterans (BO

259 pment of vaccines and therapeutics for viral diseases, models that can accurately recapitulate human

260 n the R6/2 mouse, a widely used Huntington's disease model, that integration of a rearranged transgen

261 hed light on the exciting advancement in CMT disease modelling, the breakthroughs, pitfalls, current

262 models for mechanistic biological research, disease modelling, therapeutic target identification, dr

263 n induced pluripotent stem cell (iPSC)-based disease models, tissue engineering, gene therapy, and dr

264 Coincidently we used a disease model to mirror the treatment of acetylcholine r

265 We reviewed 5 studies that used infectious disease modeling to assess the potential impact of vacci

266 For these preclinical disease models to be effective, they should both recapit

267 al CRISPR system can be used in experimental disease models to edit genomes and to control gene expre

268 r detailed investigations using Esrp1 mutant disease models to examine gene regulatory networks and p

269 ishes species members as naturally occurring disease models to investigate human hearing loss.

270 omplex tissues and are being applied to iPSC disease models to recapitulate the pathobiology of a bro

271 hPSC-COs infected by SARS-CoV-2 can serve as disease models to study SARS-CoV-2 infection and provide

272 d chronotropic incompetence and may serve as disease models to understand sinus node physiology and i

273 ogenic variant into unrelated control cells (disease modeled) to determine the necessity and sufficie

274 modify the epigenome of neoplasms and other disease models towards a more 'normal-like state', havin

275 lls (iPSCs) generates valuable resources for disease modeling, toxicology, cell therapy, and regenera

276 In contrast to other ciliopathic disease models, Tulp3 mutations do not affect ciliogenes

277 Disease modeling using cell culture and mouse models of

278 r repairing damaged cartilage or to generate disease models via gene editing.

279 -values, as well as linkage to 106 versus 99 disease models via phenotype overlap with the soft-windo

280 ology in a renal ischemia/reperfusion-injury disease model, via its effects on Wnt/beta-catenin signa

281 The disease model was integrated with established global inc

282 As a disease model we chose ischemic stroke, one of the highe

283 In the Drosophila FXS disease model, we found FMRP binds shrub mRNA (human Chm

284 n in vivo P. gingivalis-mediated periodontal disease model, we show that JAK3 inhibition enhances inf

285 (VOEs) of sickle cell disease as a vascular disease model, we show that stress promotes VOEs by elic

286 Through further analysis of neurological disease models, we determined that the immunosuppression

287 Using a combination of in vivo and ex vivo disease models, we report in this study that A20 regulat

288 N-gamma responses in the HDM allergic airway disease model were accompanied by increased disruption o

289 In those Repeat Expansion Disease models where it has been examined, expansion is

290 e were bred onto a tyrosinemia background, a disease model whereby the liver can develop disease-resi

291 Chronic recovery disease models will be required to assess safety and eff

292 utoimmune encephalomyelitis (EAE) is a mouse disease model with brain-infiltrating leukocytes.

293 after birth may be required to reverse this disease model with NPC1 gene replacement therapy.

294 d therapeutic efficacy in this Marburg virus disease model with treatment initiation 5 days post inoc

295 ward, better integration of dynamic, spatial disease models with approaches from movement ecology, la

296 thogenic deletion mutations for demonstrable disease models with both gain- and loss-of-function phen

297 In disease models with energy and 1 or more nutrient intake

298 wn to be beneficial in multiple inflammatory disease models with the effects largely attributed to re

299 m sulfate-induced chronic inflammatory bowel disease model, with efficacy similar to positive-control

300 cs have shown efficacy in rodent Alzheimer's disease models yet failed to benefit human patients.